SIBO: Diagnosis, Treatment & Diet Protocol

What Is SIBO?

The small intestine is designed to be relatively sterile. In healthy adults, bacterial counts in the jejunum stay below 10³ colony-forming units per millilitre (CFU/mL). Small intestinal bacterial overgrowth (SIBO) is defined by counts exceeding 10⁵ CFU/mL — a hundred-fold increase that fundamentally disrupts digestion, nutrient absorption, and the integrity of the gut lining.

Anatomy of the problem

The small intestine spans roughly six metres and is responsible for absorbing almost all carbohydrates, proteins, fats, vitamins, and minerals before contents reach the colon. Two mechanisms normally prevent bacterial colonisation: intestinal motility — particularly the migrating motor complex (MMC) — and the ileocecal valve, which prevents backflow of colonic bacteria.

When bacteria establish in the small intestine, they ferment carbohydrates before the host can absorb them, competing for nutrients (especially B12 and fat-soluble vitamins) and producing gases — hydrogen, methane, and hydrogen sulfide — that cause bloating, abdominal pain, altered bowel habits, and in chronic cases, significant nutritional deficiencies.

The migrating motor complex (MMC)

The MMC is the gut's housekeeping mechanism. Every 90–120 minutes between meals, a wave of peristaltic contractions sweeps the small intestine, clearing residual food particles and bacteria. This cycle requires adequate interdigestive periods — continuous snacking or grazing suppresses the MMC, allowing bacteria to accumulate. MMC dysfunction is central to virtually every case of SIBO, whether it is the cause or a consequence of the overgrowth itself.

Diagnosis: The SIBO Breath Test

The gold standard for SIBO diagnosis in clinical practice is the lactulose or glucose hydrogen/methane breath test. Both tests work on the same principle: oral ingestion of a fermentable substrate, followed by measurement of exhaled gas over two to three hours. Bacteria in the small intestine ferment the substrate and produce gases that are absorbed, transported to the lungs, and exhaled.

Lactulose vs glucose breath tests

Glucose breath tests are highly specific — glucose is almost entirely absorbed in the proximal small intestine, so any gas produced indicates overgrowth in that region. However, this makes them insensitive to more distal SIBO in the ileum. Lactulose breath tests are not absorbed at all and travel the full length of the small intestine, theoretically offering better sensitivity for distal overgrowth — though they carry a higher false-positive rate because lactulose also reaches the colon.

Hydrogen, methane, and hydrogen sulfide

The type of gas produced depends on which bacterial or archaeal species dominate the overgrowth:

• Hydrogen (H₂) SIBO: Produced by bacteria such as Escherichia coli and Klebsiella. Typically associated with diarrhoea-predominant IBS symptoms. Responds well to rifaximin monotherapy.
• Methane-dominant IMO (intestinal methanogen overgrowth): Methane is produced by archaea, not bacteria — primarily Methanobrevibacter smithii. Strongly associated with constipation. Requires rifaximin plus neomycin for adequate treatment.
• Hydrogen sulfide (H₂S) SIBO: The newest recognised subtype, associated with Fusobacterium and Desulfovibrio species. Associated with diarrhoea, flatulence with a sulfurous odour, and inflammatory symptoms. Standard breath tests do not measure H₂S — specialised tests are required.

Interpreting breath test results

North American Consensus criteria define a positive hydrogen breath test as a rise of ≥20 ppm above baseline within the first 90 minutes of a lactulose test, or ≥12 ppm for glucose. Methane positivity is defined as any reading ≥10 ppm at any point during the test. It is worth noting that Rome Consensus criteria differ slightly, and clinical interpretation should account for pre-test preparation, diet, and transit time variability.

Root Causes of SIBO

Identifying and correcting the root cause is the single most important factor in preventing relapse. The following mechanisms account for the vast majority of cases.

1. MMC dysfunction

Any condition that impairs the migrating motor complex creates conditions where bacteria can accumulate. This includes diabetes (autonomic neuropathy), hypothyroidism, scleroderma, post-infectious neuropathy (a common sequela of acute gastroenteritis), and opioid use. Food poisoning with Campylobacter or Salmonella can trigger autoimmune damage to the interstitial cells of Cajal — the pacemaker cells of the MMC — leading to chronic post-infectious SIBO.

2. Low stomach acid (hypochlorhydria)

Hydrochloric acid is the first line of defence against ingested bacteria. Chronic proton pump inhibitor (PPI) use, H. pylori infection, atrophic gastritis, and ageing all reduce gastric acid production, allowing significantly more bacteria to survive transit into the small intestine. Studies show SIBO prevalence of 50–75% in PPI users compared with 6–15% in controls.

3. Structural and anatomical factors

Adhesions from prior abdominal surgery, ileocecal valve incompetence, intestinal strictures from Crohn's disease, and jejunal diverticula all create pockets where bacteria pool and proliferate. These structural causes are particularly important to identify because no amount of antibiotic therapy will resolve SIBO if the anatomy creates a perpetual sanctuary for bacterial recolonisation.

4. Ileocecal valve dysfunction

The ileocecal valve separates the small intestine from the bacteria-rich colon. Dysfunction — either due to inflammation, chronic constipation, or anatomical variation — allows retrograde contamination of the small intestine with colonic microbiota, a subtype sometimes termed "colonic-type SIBO."

5. Prior antibiotic use

Paradoxically, antibiotics that target colonic bacteria can disrupt the competitive balance in ways that promote SIBO. Broad-spectrum antibiotics may deplete protective species while sparing or enabling small intestinal colonisers. This is distinct from using targeted antibiotics to treat SIBO — the mechanism is disruption of colonisation resistance.

SIBO Treatment Protocols

Treatment strategy should be guided by the gas type identified on breath testing. There is no one-size-fits-all protocol — hydrogen and methane SIBO require different approaches, and herbal protocols offer a viable alternative to antibiotics with comparable efficacy data.

Rifaximin (hydrogen-dominant SIBO)

Rifaximin (brand name Xifaxan) is a non-absorbable antibiotic that acts exclusively within the GI tract, with minimal systemic side effects and low risk of systemic antimicrobial resistance. The landmark Pimentel et al. trial established rifaximin 550 mg three times daily for 14 days as the standard of care for hydrogen-dominant SIBO, achieving approximately 70% eradication on breath test normalisation and significant improvement in IBS symptoms. Its non-absorbable nature also preserves systemic microbiome diversity far better than traditional antibiotics.

Rifaximin + neomycin (methane-dominant IMO)

Methane-producing archaea are not bacteria and do not respond adequately to rifaximin alone. Clinical data supports combining rifaximin 550 mg three times daily with neomycin 500 mg twice daily for 14 days in methane-dominant cases. The combination works by using rifaximin to reduce hydrogen production (which methanogens consume) while neomycin targets the archaea directly. Breath test normalisation rates of approximately 87% have been reported with combination therapy versus 33% with rifaximin alone in methane-positive patients.

Herbal SIBO protocol

A pivotal 2014 study by Chedid et al. (published in Global Advances in Health and Medicine) found that two commercial herbal antimicrobial formulations achieved SIBO eradication rates equivalent to rifaximin — approximately 46% versus 34% — with the herbal group showing numerically superior outcomes in some analyses. Key herbal agents with evidence include:

• Allicin (garlic extract): Broad-spectrum antimicrobial and anti-archaeal activity, particularly effective against methane-producing organisms. Dose: 450–900 mg allicin/day.
• Berberine: Inhibits bacterial growth and biofilm formation; also improves intestinal motility — a dual action that addresses both the overgrowth and its underlying driver. Dose: 500 mg three times daily.
• Neem (Azadirachta indica): Broad-spectrum antibacterial and anti-biofilm agent, commonly included in commercial herbal SIBO formulations.
• Oil of oregano (carvacrol): Potent antimicrobial with activity against gram-positive and gram-negative organisms.
• Partially hydrolysed guar gum (PHGG): A prebiotic fibre that also supports MMC function when combined with antimicrobial treatment.

Herbal protocols typically run for 4–6 weeks, longer than antibiotic courses, and are often preferred by patients seeking to avoid antibiotic side effects or who have already undergone multiple rifaximin courses.

Elemental diet

The elemental diet is the most aggressive non-antibiotic treatment option and the one with the highest eradication rate. Elemental formulas contain pre-digested nutrients (amino acids, simple sugars, medium-chain triglycerides) that are absorbed almost entirely in the proximal small intestine, starving bacteria of fermentable substrate. A 2-week course has demonstrated up to 80–84% breath test normalisation. The principal barrier is palatability and cost — elemental formulas are often bland, expensive, and require complete replacement of normal eating for the duration. They are most appropriate for severe, recalcitrant, or multiply-relapsed SIBO.

Diet During SIBO Treatment

Diet does not cure SIBO, but it profoundly affects symptom burden during treatment and may influence how rapidly bacteria are starved or recolonise post-treatment. The goal is to reduce fermentable substrate in the small intestine while maintaining adequate nutrition.

Low-FODMAP diet

The low-FODMAP diet (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) was developed at Monash University to manage IBS symptoms. It does not treat SIBO but dramatically reduces gas production and symptomatic bloating by limiting the substrate available to bacteria. Studies report 50–76% of IBS patients experience meaningful symptom reduction on low-FODMAP. However, the diet is restrictive and inadvisable long-term due to its prebiotic-restricting effects on beneficial colonic bacteria.

Specific Carbohydrate Diet (SCD)

The SCD eliminates all complex carbohydrates — grains, sugar, lactose, and starches — while permitting monosaccharides (glucose, fructose in fruit), meats, eggs, non-starchy vegetables, and specific cheeses. The rationale is that complex carbohydrates provide fermentable substrate for bacterial overgrowth while monosaccharides are absorbed quickly before reaching bacterial colonies. Many SIBO practitioners combine elements of the SCD with low-FODMAP into a hybrid "SIBO-specific food guide."

What to eat during treatment

• Proteins: All meats, fish, poultry, eggs — these are negligible fermentation substrates
• Low-FODMAP vegetables: Zucchini, cucumbers, leafy greens, bell peppers, green beans, tomatoes (small amounts), carrots
• Low-FODMAP fruits: Blueberries, strawberries, cantaloupe, kiwi, oranges (small portions)
• Fats and oils: Olive oil, coconut oil, butter, avocado (small amounts) — fats are not fermented
• Starches (limited): White rice, white potato (cooled), sourdough made with extended fermentation

What to avoid during treatment

• High-FODMAP foods: Garlic, onion, wheat, rye, legumes, lentils, apples, pears, honey, lactose
• Fibre supplements (psyllium, inulin, FOS) — highly fermentable and dramatically worsens symptoms
• Alcohol — impairs MMC and feeds bacterial overgrowth
• Continuous grazing — suppresses the MMC; aim for 4–5 hours between meals to allow housekeeping sweeps
• Probiotics during active treatment — controversial but many practitioners pause them until breath test normalises

Reintroduction phase

After confirmed eradication (ideally via repeat breath test), foods should be reintroduced gradually — one new food every 3 days, monitoring for symptom recurrence. This phase is critical: premature reintroduction of high-FODMAP foods before root causes are addressed is a common driver of early relapse. Many practitioners recommend maintaining a modified low-FODMAP diet for 4–6 weeks post-treatment before full reintroduction.

Clinical Evidence Summary